Stockscreener 앱 받기
19.73
2.86%
-0.58
시간 외 거래:
19.62
-0.11
-0.56%
전일 마감가:
$20.31
열려 있는:
$20.22
하루 거래량:
1.05M
Relative Volume:
0.70
시가총액:
$3.40B
수익:
$1.10B
순이익/손실:
$375.65M
주가수익비율:
8.9833
EPS:
2.1963
순현금흐름:
$113.59M
1주 성능:
+3.19%
1개월 성능:
-22.41%
6개월 성능:
-10.76%
1년 성능:
-9.20%
1일 변동 폭
$19.58
$20.25
1주일 범위
$19.11
$20.57
52주 변동 폭
$18.39
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
19.73 | 3.40B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2026-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-23 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research
Needham keeps USD 35.00 target for ACADIA Pharmaceuticals stock - ad-hoc-news.de
FDA Approval for DAYBUE STIX issued to ACADIA PHARMS INC - Quantisnow
ACADIA Pharmaceuticals stock has a USD 31.34 consensus target from 18 analysts - ad-hoc-news.de
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada
ACADIA Pharmaceuticals (ACAD) Stock Forecast and Price Target 2026 $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. (0A4W.IL) stock price, news, quote and history - Yahoo Finance UK
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
UBS cuts target for ACADIA Pharmaceuticals stock to USD 23.00 - ad-hoc-news.de
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Law firm probes ACADIA investors' claims after trial misses key endpoint, stock drops sharply. - Pluang
Acadia Pharmaceuticals stock hits 52-week low at 19.01 USD - Investing.com
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target - Yahoo Finance
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
RBC keeps Outperform on ACADIA Pharmaceuticals stock at USD 37 - AD HOC NEWS
RBC reiterates Outperform on ACADIA Pharmaceuticals stock - AD HOC NEWS
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook - GuruFocus
RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments - Investing.com
Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent L - GuruFocus
ACADIA Pharmaceuticals Inc. (0A4W.IL) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia
Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - biospace.com
Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - Yahoo Finance
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acadia Pharmaceuticals Inc 주식 (ACAD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 06 '26 |
Sale |
29.22 |
14,292 |
417,604 |
67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Option Exercise |
17.84 |
5,849 |
104,346 |
73,677 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Sale |
29.00 |
5,849 |
169,638 |
67,828 |
| Schneyer Mark C. | Officer |
Aug 05 '26 |
Proposed Sale |
27.15 |
5,849 |
158,800 |
0 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev |
Jul 30 '26 |
Sale |
26.13 |
16,558 |
432,663 |
18,994 |
| Kihara James | Officer |
Jun 26 '26 |
Proposed Sale |
26.00 |
11,421 |
297,000 |
0 |
| JAMES K KIHARA | Officer |
May 26 '26 |
Proposed Sale |
21.18 |
5,401 |
114,394 |
0 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 26 '26 |
Sale |
21.18 |
5,401 |
114,393 |
24,509 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 04 '26 |
Sale |
21.79 |
1,332 |
29,024 |
29,129 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
21.79 |
3,506 |
76,396 |
66,145 |
3.18%
자본화:
|
볼륨(24시간):